| Literature DB >> 18156491 |
Jotin Marango1, Manabu Shimoyama, Hitomi Nishio, Julia A Meyer, Dong-Joon Min, Andres Sirulnik, Yolanda Martinez-Martinez, Marta Chesi, P Leif Bergsagel, Ming-Ming Zhou, Samuel Waxman, Boris A Leibovitch, Martin J Walsh, Jonathan D Licht.
Abstract
MMSET, identified by its fusion to the IgH locus in t(4;14)-associated multiple myeloma, possesses domains found within chromatin regulators, including the SET domain. MMSET protein is overexpressed and highly associated with chromatin in myeloma cell lines carrying t(4;14). MMSET possesses methyltransferase activity for core histone H3 lysine 4 and histone 4 lysine 20, whereas MMSET made in cells only modified H4. Segments of MMSET fused to the Gal4 DNA binding domain repressed transcription of a chromatin-embedded Gal4 reporter gene. MMSET-mediated repression was associated with increased H4K20 methylation gene and loss of histone acetylation. Consistent with this repressive activity, MMSET could form a complex with HDAC1 and HDAC2, mSin3a, and the histone demethylase LSD1, suggesting that it is a component of corepressor complexes. Furthermore, MMSET coexpression enhances HDAC1- and HDAC2-mediated repression in transcriptional reporter assays. Finally, shRNA-mediated knockdown of MMSET compromised viability of a myeloma cell line, suggesting a biologic role for the protein in malignant cell growth. Collectively, these data suggest that, by acting directly as a modifier of chromatin as well as through binding of other chromatin-modifying enzymes, MMSET influences gene expression and potentially acts as a pathogenic agent in multiple myeloma.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18156491 PMCID: PMC2265454 DOI: 10.1182/blood-2007-06-092122
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113